AstraZeneca (AZN) DIvidends Date & History

Key Takeaways

• AstraZeneca maintains a progressive dividend policy focused on long-term growth rather than high current yield.
• Current annualized dividend totals approximately $3.20 per share, delivering a yield near 1.9%.
• The company pays dividends semi-annually, with the most recent ex-dividend date on February 20, 2026.
• Payout ratio stands at roughly 47-48%, indicating strong earnings coverage and sustainability.
• Dividend growth has been consistent, supported by robust free cash flow and a healthy balance sheet.
• The stock appeals primarily to long-term dividend growth investors seeking stability in the pharmaceutical sector.

Dividend Overview

AstraZeneca follows a progressive dividend policy, intending to maintain or increase payouts annually while balancing business investment and shareholder returns. The company distributes dividends twice per year. The most recent payment reflects an annualized rate of about $3.20 per share, resulting in a forward yield near 1.9% based on recent share prices. This profile positions AZN as a modest-yield dividend stock rather than a high-yield income vehicle, with emphasis on sustainable growth over time.

Dividend History and Growth

AstraZeneca has demonstrated consistent dividend payments with gradual increases aligned to its earnings outlook. Recent semi-annual distributions include $2.17 and $1.03 per share in the latest cycle. Over multiple years, the company has raised its dividend at a measured pace, reflecting a strategy of steady growth rather than aggressive hikes. No significant cuts have occurred recently, underscoring reliability through economic cycles and R&D investments typical of the pharmaceutical industry.

Dividend Sustainability and Payout Ratio

The dividend appears well-supported, with a payout ratio of approximately 47-48% of earnings. This level leaves ample room for reinvestment and future increases. Strong free cash flow generation and a solid investment-grade credit rating further enhance sustainability. AstraZeneca’s balance sheet remains stable, enabling continued payments even amid pipeline development costs and sector volatility.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, AstraZeneca’s yield of around 1.9% sits modestly below some peers with higher payouts but aligns with growth-oriented companies prioritizing R&D. Competitors often feature yields ranging from 1.5% to 3.5%, depending on maturity and cash flow profiles. AZN stands out for its lower payout ratio and emphasis on long-term dividend progression compared to more mature peers offering higher current income.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Is This Stock Attractive for Dividend Investors?

AstraZeneca suits dividend growth investors and long-term holders who prioritize sustainable increases over immediate high yield. Its modest payout ratio and progressive policy appeal to those seeking compounding income within the healthcare sector. Conservative income-focused investors may find the current yield less compelling compared to higher-yielding alternatives, while those emphasizing capital appreciation alongside dividends could view the stock favorably. The company’s financial strength supports ongoing distributions without undue risk to the payout.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations